Pharmacological management of undifferentiated spondyloarthropathies

Expert Opinion on Investigational Drugs

Volumn 15, Issue 1, 2006, Pages 39-46

  Palazzi, Carlo ^a   Padula, Angela ^b   Montaruli, Maria ^b   Pennese, Ernesta ^b   Olivieri, Ignazio ^b  

^a 'Villa Pini' Clinic   (Italy)

^b Ospedale Civile di Matera   (Italy)

Author keywords

Spondylarthritis; Spondyloarthritides; Spondyloarthropathies; Undifferentiated spondyloarthropathies

Indexed keywords

ADALIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CIPROFLOXACIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; ETANERCEPT; FOLIC ACID; HLA B27 ANTIGEN; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NERIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; RIFAMPICIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; BONE MARROW DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG MECHANISM; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MUCOSA; REVIEW; SIDE EFFECT; SKIN DISEASE; SPONDYLOARTHROPATHY; SYMPTOMATOLOGY; TREATMENT INDICATION; UNDIFFERENTIATED SPONDYLOARTHROPATHY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; PREVALENCE; SPONDYLARTHROPATHIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 29944433278     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.1.39     Document Type: Review

References (88)

1. MOLL JMH, HASLOCK I, WRIGHT V: Seronegative spondarthritides. In: Copeman's Textbook of the Rheumatic Disease. Scott JT (Ed.), Churcill Livingstone, Edinburgh, UK (1986) 2:723-44.
2. KHAN MA, VAN DER LINDEN: A wider spectrum of spondyloarthropathies. Semin. Arthritis Rheum. (1990) 20:107-113.
3. KHAN MA, VAN DER LINDEN SM: Undifferentiated spondyloarthropathies. In: Ankylosing Spondylitis and Related Spondyloarthropathies. Khan MA (Ed.) Hanley & Belfits, Philadelphia, USA (1990):657-664.
4. ZEIDLER H, MAW W. KHAN MA: Undifferentiated spondyloarthropathies. Rheum. Dis. Clin. North Am. (1992) 18:187-202.
5. SIEPER J, RUDWALEIT M, BRAUN J, VAN DER HEIJDE D: Diagnosing reactive arthritis: role of clinical setting in the value of serologic microbiologic assays. Arthritis Rheum. (2002) 46:319-327.
6. OLIVIERI I, CIANCIO, G, PADULA A et al.: Psoriatic arthritis sine psoriasis: a study of 20 consecutive patients. Arthritis Rheum. (2000) 43:S 105.
7. SCARPA R, COSENTINI E, MANGUSO F et al.: Clinical and genetic aspects of psoriatic arthritis 'sine psoriasis'. J. Rheumatol. (2003) 30:2638-2640.
8. REZAIAN MM: Undifferentiated spondyloarthropathy: seven years follow-up study of 457 patients. Arthritis Rheum. (2000) 43:S93 (Supplement).
9. AMOR B, DOUGADOS M, MIJIYAWA M: Critéres de classification des spondylarthropathies. Rev. Rhum. (1990) 57:85-89.
10. DOUGADOS M, VAN DER LINDEN S, JUHLIN R et al.: The European Spondylarthropathy Study Group for he classification of spondylarthropathy. Arthritis Rheum. (1991) 34:1218-1227.
11. BOYER GS, TEMPLIN DW, GORING WP: Evaluation of the European Spondylarthropathy Study Group preliminary classification criteria in Alaskan Eskimos populations. Arthritis Rheum. (1993) 36:434-438.
12. COLLANTES-ESTEVEZ E, CISNAL DEL MAZO A, MUNOZ-GOMARIZ E: Assessment of two systems of spondyloarthropathy diagnostic and classification criteria (Amor and ESSG) by a Spanish multicenter study. J. Rheumatol. (1995) 22:246-251.
13. ERTURK M, ALACA R, TOSUM E, DURUOZ MT. Evaluation of the Amor and ESSG classification criteria for spondyloarthropathies in a Turkish population. Rev. Rhum. (English Edition) (1997) 64:293-300.
14. BADDOURA R, AWADA H, OKAIS J et al.: Validation of the European Spondyloarthropathy Study Group and B. Amor criteria for spondyloarthropathy in Lebanon. Rev. Rhum. (English Edition). (1997) 64:459-464.
15. OLIVIERI I, CANTINI F, SALVARANI C: Diagnostic and classification criteria, clinical and functional assessment, and therapeutic advances for spondyloarthropathies. Curr. Opin. Rheumatol. (1997) 9:284-290.
16. OLIVIERI I, PADULA A, PIERRO A. Late onset undifferentiated seronegative spondyloarthropahy. J. Rheumatol. (1995) 22:899-903.
17. BOYER GS, TEMPLIN DW, CORNONI-HUNTLEY JC et al.: Prevalence of spondyloarthropathies in Alaskan Eskimos. J. Rheumatol. (1994) 21:2292-2297.
18. BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. (1998) 41:58-67.
19. D'AMATO M, FIORILLO MT, CARCASSI C et al.: Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur. J. Immunol. (1995) 25:3199-3201.
20. OLIVIERI I, CIANCIO G, PADULA A et al.: The HLA-B*2709 subtype confers susceptibility to spondyloarthropathy. Arthritis Rheum. (2002) 46:553-554.
21. OLIVIERI I, PADULA A, CIANCIO G et al.: The HLA-B*2709 subtype in a patient with undifferentiated spondyloarthritis. Ann. Rheum. Dis. (2000) 59:654-655.
22. BOYER GS, TEMPLIN DW, BOWLER A et al.: Spondyloarthropathy in the community: differences in severity and disease expression in Alaskan Eskimo men and women. J. Rheumatol. (2000) 27:170-176.
23. OLIVIERI I, SALVARANI C, CANTINI F, CIANCIO G, PADULA A. Ankylosing spondylitis and undifferentiated spondyloarthropathy: a clinical review and description of a disease subset with older age at onset. Curr. Opin. Rheumatol. (2001) 13:280-284.
24. SAMBROOK P, McGUIGAN L, CHAMPION D et al.: Clinical features and follow-up study of HLA-B27 positive patients presenting with peripheral arthritis. J. Rheumatol. (1985) 12:526-528.
25. OLIVIERI I, BAROZZI L, PADULA A: Enthesiopathy: clinical manifestations, imaging and treatment. Baillieres Clin. Rheumatol. (1998) 12:665-681.
26. SIEGEL DM, BRAUM J: HLA-B27 associated dactylitis in children. J. Rheumatol. (1988) 15:976-977.
27. PADULA A, SCARANO E, GIASI V, OLIVIERI I: Juvenile onset isolated B27 associated dactylitis. Semin. Arthritis Rheum. (2003) 32:341-342.
28. PADULA A, GIASI V, OLIVIERI I: Elderly onset isolated B27 associated dactylitis. Ann. Rheum. Dis. (2002) 61:759-760.
29. KHAN MA, VAN DER LINDEN S, KUSHNER I et al.: Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients. Arthritis Rheum. (1985) 28:40-43.
30. VAN DER LINDEN SA, KHAN MA, RENTSCH HV et al.: Chest pain without radiographic sacroiliitis in relatives of patients with ankylosing spondylitis. J. Rheumatol. (1988) 15:836-839.
31. SAARI KM, SOLJA J, HAKLI J: Genetic background of acute anterior uveitis. Am. J. Ophthalmol. (1981) 91:711-720.
32. BERGFELDT L, INSULANDER P, LINDBLOM D et al: HLA-B27: an important genetic risk factor for lone aortic regurgitation and severe conduction system abnormalities. Am. J. Med. (1988) 85:12-18.
33. MIJIYAWA M, ONIANKITAN O, KHAN MA: Spondyloarthropathies in sub-Saharan Africa. Curr. Opin. Rheumatol. (2000) 12:280-284.
34. NJOBVU P, McGILL P, KERR H et al.: Spondyloarthropathy and human immunodeficiency virus infection in Zambia. J. Rheumatol. (1998) 25:1553-1559.
35. ROSEMBERG AM, PETTY RE: A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum. (1982) 25:1041-1047.
36. JACOBS JC, BERDON WE, JOHNSTON AD: HLA-B27-associated spondyloarthrtis and enthesopathy in childhood: clinical, pathologic, and radiolographic observation in 58 patients. J. Pediatr. (1982) 100:521-528.
37. PRIEUR AM, LISTRAT V, DOUGADOS M, AMOR B: Critères de classification des spondylarthropathies chez les infantes. Arch. Fr. Pediatr. (1993) 50:379-385.
38. PETTY RE, SOUTHWOOD TR, BAUM J et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J. Rheumatol. (1998) 25:1991-1994.
39. BURGOS-VARGAS R, CLARK P: Axial involvement in the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J. Rheumatol (1989) 16:192-197.
40. OLIVIERI I, FOTO M, RUJU GP et al: Low frequency of axial involvement in Caucasian pediatric patients with seronegative enthesopathy and arthropathy syndrome after 5 years of disease. J. Rheumatol. (1992) 19:469-475.
41. MAU W. ZEIDLER H, MAU R et al.: Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J. Rheumatol. (1988) 15:1109-1114.
42. SAMPAIO-BARROS PD, BERTOLO MB, KRAEMER MH, MARQUES-NETO JF, SAMARA AM: Undifferentiated spondyloarthropathies: a 2-year follow-up study. Clin. Rheumatol. (2001) 20:201-206.
43. DUBOST JJ, SAUVEZIE B: Late onset peripheral spondyloarthropathy. J. Rheumatol. (1989) 16:1214-1217.
44. 3PE syndrome. J. Am. Med. Assoc. (1985) 254:2763-2767.
45. RUSSELL EB, HUNTER JB, PEARSON L et al.: Remitting seronegative, symmetrical synovitis with pitting edema: 13 additional cases. J. Rheumatol. (1990) 17:633-639.
46. McCARTY DJ: Clinical picture of rheumatoid arthritis. In: Arthritis and allied conditions, McCarty DJ, Koopman WJ (Eds), Lea & Febiger, Philadelphia, USA (1993) 12:781-809.
47. DUBOST JJ, RISTORI JM, ZMANTAR C et al.: Rhumatismes séronégatifs a deb́ut tardif: fréquence et atypies des spondylarthropathies. Rev. Rhum. (1991) 58:577-584.
48. OLIVIERI I., ORANGES GS, SCONOSCIUTO F et al.: Late onset peripheral seronegative spondyloarthropathy: report of two additional cases. J. Rheumatol. (1993) 20:390-393.
49. BRAUN J, BARALIAKOS X, GODOLIAS G, BÖHM H. Therapy of ankylosing spondylitis - a review. Part I: conventional medical treatment and surgical therapy. Scand. J. Rheumatol. (2005) 34:97-108.
50. BRAUN J, BARALIAKOS X, BRANDT J, SIEPER J.: Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand. J. Rheumatol. (2005) 34:178-190.
51. BRAUN J, VAN DER HEIJDE D: Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert. Opin. Investig. Drugs (2003) 12:1097-1109.
52. PRAYAD R, GLADMAN D: Current and investigational treatment of psoriatic arthritis. Expert. Opin. Investig. Drugs (2004) 13:139-150.
53. PALAZZI C, OLIVIERI I, D'AMICO E, PENNESE E, PETRICCA A: Management of reactive arthritis. Expert. Opin. Pharmacother. (2004) 5:61-70.
54. ZOCHLING J, BRANDT J, BRAUN J: The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (2005) (In Press).
55. AMOR B, DOUGADOS M, KHAN MA. Management of refractory ankylosing spondylitis and related spondylarthropathies. Rheum. Dis. Clin. North Am (1995) 21:117-128.
56. SPIEGEL BM, CHIOU CF, OFMAN JJ: Minimizing complications from nonsteroidal anti-inflammatory drugs: cost-effectivenes of competing strategies in varying risk groups. Arthritis Rheum. (2005) 52:185-197.
57. WANDERS A, VAN DER HEIJDE D, LANDEWÉ R et al.: Inhibition of radiographic progression in ankylosing spondylitis by continuous use of NSAIDs. Arthritis Rheum. (2005) 52:1756-1765.
58. TOIVANEN A: Managing reactive arthritis. Rheumatology (Oxford) (2000) 39(2):117-119.
59. GRASSI W, DE ANGELIS R, CERVINI C: Corticosteroids prescribing in rheumatoid arthritis and psoriatic arthritis. Clin. Rheumatol. (1998) 17:223-226.
60. MINTZ G, ENRIQUEZ RD, MERCADO U, ROBLES EJ, JIMENEZ FJ, GUTIERREZ G: Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Arthritis Rheum. (1981) 24:734-736.
61. RICHTER MB, WOO R PANAYI GS, TRULL A, UNGER A, SHEPHERD P: The effects of intravenous pulse methylprednisolone therapy in ankylosing spondylitis. Clin. Exp. Immunol. (1983) 53:51-59.
62. PETERS ND, EJSTRUP L: Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand. J. Rheumatol. (1992) 21:134-138.
63. MAUGARS Y, MATHIS C, BERTHELOT J, CHARLIER C, PROST A: Assessment of the efficacy of sacroiliac corticosteroid injections in spondyloartliropathies: a double blind study. Br. J. Rheumatol (1996) 35:767-770.
64. BRAUN J, BRANDT J, LISTING J, RUDWALEIT M, SIEPER J: Biologic therapies in the spondyloarthritis: new opportunities, new challenges. Curr. Opin. Rheumatol. (2003) 15(4):394-407.
65. TOUSSIROT E, WENDLING D: Recent progress in ankylosing spondylitis treatment. Expert Opin. Pharmacother. (2003) 4(1):1-12.
66. ABU-SHAKRA M, GLADMAN DD, THORNE JC: Longterm methorrexate therapy in psoriatic arthritis: clinical and radiological outcome. J. Rheumatol. (1995) 22:241-245.
67. RAHMAN P; GLADMAN DD, COOK RJ, ZHOU Y, YOUNG G: The use of sullasalazine in psoriatic arthritis: a clinic experience. J. Rheumatol. (1998) 25:1957-1961.
68. MACCHIONI P. BOIARDI L, CREMONESI T et al.: The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. Rheumatol. Int. (1998) 18:27-33.
69. HAIBEL H, BRANDT HC, RUDWALEIT M et al.: Preliminary results of an open-label, 12-week trial of adalimumab in the treatment of active ankylosing spondylitis, Ann. Rheum. Dis. (2004) 64(Suppl. 1):399.
70. BRAUN J, BARALIAKOS X, GOLDER W et al.: Magnetic resonance imaging examination of the spine in patients with ankylosing spondylitis, before ad after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. (2003) 48:1126-1136.
71. RUDWALEIT M, BARALIAKOS X, LISTING J, BRANDT J, SIEPER J, BRAUN J: Magnetic resonance imaging examination of the spine and the sacroiliac joints in ankylosing spondylitis before ad during therapy with etanercept. Ann. Rheum. Dis. (2005) 64:1305-1310.
72. BARALIAKOS X, DAVIS J, TSUJI W, BRAUN J: Magnetic resonance imaging examination of the spine in patients with ankylosing spondylitis, before ad after therapy with the tumor necrosis factor α receptor fusion protein etanercept. Arthritis Rheum. (2005) 52:1216-1223
73. BARALLIAKOS Y, LISTING J, RUDWALEIT M, BRANDT J, SIEPER J, BRAUN J: Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-α antibody infliximab. Ann. Rheum. Dis. (2005) 64:1462-1466.
74. TOUSSIROT E, WENDLING D: Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthopathies. Expert Opin. Pharmacother. (2005) 6:35-43.
75. MAKSYMOWYCH WP, JHANGRI GS, LECLERCQ S, SKEITH KJ, YAN A, RUSSELL AS: An open study of pamidronate in the treatment of refractory ankylosingspondylitis. J. Rheumatol. (1998) 25:714-717.
76. MAKSYMOWYCH WP LAMBERT R; JHANGRI GS et al.: Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J. Rheumatol. (2001) 28:144-155.
77. HAIBEL H, BRANDT J, RUDWALEIT M, SOERENSEN H; SIEPER J, BRAUN J: Treatment of active ankylosing spondylitis. Rheumatology (2003) 42:1018-1020.
78. MAKSYMOWYCH WP, JHANGRI GS, FITZGERALD AA et al.: A six-month randomized, controlled, double blind, dose-rrsponse comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of non steroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. (2002) 46:766-773.
79. SIEPER J, FENDLER C, LAITKO S et al.: No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis. Arthritis Rheum. (1999) 42:1386-1396.
80. SMIEJA M, MacPHERSON DW, KEAN W et al.: Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. Ann. Rheum. Dis. (2001) 60(12):1088-1094.
81. CARTER JD, VALERIANO J, VASEY FB: Doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomised 9-month comparison. J. Rheumatol. (2004) 31:1973-1980.
82. BRAUN J, ALTEN R, BURMESTER G et al.: A placebo-controlled multicenter study of the efficacy and tolerance of sulfasalazine in early undifferentiated spondyloarthropathy. Ann. Rheum. Dis. (2004) 63(Suppl. 1):413.
83. DOUGADOS M, VAN DER LINDEN S, LEIRISALO-REPO M et al.: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. (1995) 38(5):618-627.
84. CLEGG DO, REDA DJ, WEISMAN MH et al.: Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. (1996) 39(12):2021-2027.
85. CLEGG DO, REDA DJ, ABDELLATIF M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropatliies: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum. (1999) 42(11):2325-2339.
86. BRANDT J, HAIBEL H, REDDIG J, SIEPER J, BRAUN J: Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antiobody infliximab. J. Rheumatol. (2002) 29:118-122.
87. SCHNARR S, HUELSEMANN JL, MERKESDAL S et al.: Anti-tumor necrosis factor-alpha therapy with the chimeric monoclonal antibody infliximab in severe undifferentiated spondyloarthropathy. Ann. Rheum. Dis. (2004) 63(Suppl. 1):422.
88. BRANDT J, KHARIOUZOV A, LISTING J et al.: Successful short treatment of patients with severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J. Rheumatol. (2004) 31:531-538.